Ranibizumab (Lucentis) in neovascular age-related macular degeneration: Evidence from clinical trials

British Journal of Ophthalmology

Volumn 94, Issue 1, 2010, Pages 2-13

  Mitchell, P ^a   Korobelnik, J F ^b   Lanzetta, P ^c   Holz, F G ^d   Prunte C ^e   Schmidt Erfurth, U ^e   Tano, Y ^f   Wolf, S ^g  

^a UNIVERSITY OF SYDNEY   (Australia)

^b BORDEAUX UNIVERSITY HOSPITAL   (France)

^c UNIVERSITY OF UDINE   (Italy)

^d UNIVERSITY OF BONN   (Germany)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

^f OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^g UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB; VERTEPORFIN;

BRAIN INFARCTION; CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; ENDOPHTHALMITIS; EYE EXAMINATION; EYE INJURY; HEART INFARCTION; HUMAN; HYPERTENSION; NEOVASCULAR AGE RELATED RETINA MACULA DEGENERATION; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; RETINA DETACHMENT; RETINA FOVEA; RETINA HEMORRHAGE; RETINA MACULA DEGENERATION; RETINA TEAR; REVIEW; SHAM PROCEDURE; STROKE; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; TREATMENT OUTCOME; UVEITIS; VISUAL ACUITY; VISUAL IMPAIRMENT; VITREOUS HEMORRHAGE;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; DRUG ADMINISTRATION SCHEDULE; EVIDENCE-BASED MEDICINE; HUMANS; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; WET MACULAR DEGENERATION;

EID: 74549137478     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjo.2009.159160     Document Type: Review

References (75)

1. Bressler NM. Age-related macular degeneration is the leading cause of blindness. JAMA 2004;291:1900-1.
2. Friedman DS, O'Colmain BJ, Munoz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004;122:564-72.
3. Resnikoff S, Pascolini D, Etya'ale D, et al. Global data on visual impairment in the year 2002. Bull World Health Organ 2004;82:844-51.
4. Wong T, Chakravarthy U, Klein R, et al. The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. Ophthalmology 2008;115:116-26.
5. Brown MM, Brown GC, Stein JD, et al. Age-related macular degeneration: economic burden and value-based medicine analysis. Can J Ophthalmol 2005;40:277-87.
6. Ferrara N, Damico L, Shams N, et al. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 2006;26:859-70.
7. Lowe J, Araujo J, Yang J, et al. Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo. Exp Eye Res 2007;85:425-30.
8. Grisanti S, Tatar O. The role of vascular endothelial growth factor and other endogenous interplayers in age-related macular degeneration. Prog Retin Eye Res 2008;27:372-90.
9. Penn JS, Madan A, Caldwell RB, et al. Vascular endothelial growth factor in eye disease. Prog Retin Eye Res 2008;27:331-71.
10. Oester A, Baffi J, Ambati BK. Pharmacotherapy targeting ocular neovascularization. Focal Points 2008;XXVI:1-10.
11. Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. Pegaptanib for neovascular age-related macular degeneration. New Engl J Med 2004;351:2805-16.
12. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. New Engl J Med 2006;355:1432-44.
13. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. New Engl J Med 2006;355:1419-31.
14. Blick SK, Keating GM, Wagstaff AJ. Ranibizumab. Drugs 2007;67:1199-206.
15. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005;36:331-5.
16. Ip MS, Scott IU, Brown GC, et al. Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration: a report by the American Academy of Ophthalmology. Ophthalmology 2008;115:1837-46.
17. Amoaku W. Ranibizumab: The clinician's guide to commencing, continuing, and discontinuing treatment. Eye. In press.
18. Amoaku WM. The Royal College of Ophthalmologists interim recommendations for the management of patients with age-related macular degeneration. Eye 2008;22:864-8.
19. Chakravarthy U, Soubrane G, Bandello F, et al. Evolving European guidance on the medical management of neovascular age related macular degeneration. Br J Ophthalmol 2006;90:1188-96.
20. Schmidt-Erfurth UM, Richard G, Augustin A, et al. Guidance for the treatment of neovascular age-related macular degeneration. Acta Ophthalmol Scand 2007;85:486-94.
21. Brown DM, Regillo CD. Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients. Am J Ophthalmol 2007;144:627- 37.
22. Dadgostar H, Waheed N. The evolving role of vascular endothelial growth factor inhibitors in the treatment of neovascular age-related macular degeneration. Eye 2008;22:761-7.
23. Regillo CD, Brown DM, Abraham P, et al. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 2008;145:239-48.
24. Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology 2009;116:57-65.
25. Chang TS, Bressler NM, Fine JT, et al. Improved vision-related function after ranibizumab treatment of neovascular age-related macular degeneration: results of a randomized clinical trial. Arch Ophthalmol 2007;125:1460-9.
26. Boyer DS, Antoszyk AN, Awh CC, et al. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007;114:246-52.
27. Bressler NM, Chang TS, Fine JT, et al. Improved vision-related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Arch Ophthalmol 2009;127:13-21.
28. Kaiser PK, Brown DM, Zhang K, et al. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol 2007;144:850-7.
29. Eyeworld.org. Lucentis at one year. http://www.eyeworld.org/ printarticle.php?id=4390 (accessed 21 Nov 2008).
30. Meyer CH, Eter N, Holz FG, et al. Ranibizumab in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Interim results from the SUSTAIN trial [abstract]. Invest Ophthalmol Vis Sci 2008;49:E-abstract 273.
31. Bolz M, Schmidt-Erfurth U. Ranibizumab EXCITE study: Exploring the value of optical coherence tomography for the management of ranibizumab therapy in age-related macular degeneration. 2008. 8th EURETINA Congress, 22-25 May 2008, Vienna.
32. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007;143:566-83.
33. Ferris FL III, Kassoff A, Bresnick GH, et al. New visual acuity charts for clinical research. Am J Ophthalmol 1982;94:91-6.
34. Rosser DA, Laidlaw DA, Murdoch IE. The development of a "reduced logMAR" visual acuity chart for use in routine clinical practice. Br J Ophthalmol 2001;85:432-6.
35. Falkenstein IA, Cochran DE, Azen SP, et al. Comparison of visual acuity in macular degeneration patients measured with Snellen and early treatment diabetic retinopathy study charts. Ophthalmology 2008;115:319-23.
36. Barbazetto I, Burdan A, Bressler NM, et al. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment - TAP and VIP report No. 2. Arch Ophthalmol 2003;121:1253-68.
37. Ahlers C, Golbaz I, Stock G, et al. Time course of morphologic effects on different retinal compartments after ranibizumab therapy in age-related macular degeneration. Ophthalmology 2008;115:e39- 46.
38. Liakopoulos S, Ongchin S, Bansal A, et al. Quantitative optical coherence tomography findings in various subtypes of neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 2008;49:5048-54.
39. Yannuzzi LA, Sorenson J, Spaide RF, et al. Idiopathic polypoidal choroidal vasculopathy (IPCV). Retina 1990;10:1-8.
40. Spaide RF, Yannuzzi LA, Slakter JS, et al. Indocyanine green videoangiography of idiopathic polypoidal choroidal vasculopathy. Retina 1995;15:100-10.
41. Yannuzzi LA, Negrao S, Iida T, et al. Retinal angiomatous proliferation in age-related macular degeneration. Retina 2001;21:416-34.
42. Gross NE, Aizman A, Brucker A, et al. Nature and risk of neovascularization in the fellow eye of patients with unilateral retinal angiomatous proliferation. Retina 2005;25:713-18.
43. Freund KB, Ho IV, Barbazetto IA, et al. Type 3 neovascularization: the expanded spectrum of retinal angiomatous proliferation. Retina 2008;28:201-11.
44. Position of the Retinological Society, the German Ophthalmological Society and the Professional Association of Ophthalmologists in Germany on the current therapeutic possibilities for neovascular age-related macular degeneration. Klin Monatsbl Augenheilkd 2007;224:559-66.
45. Verteporfin Roundtable 2000 and 2001 Participants, Treatment of age-related macular degeneration with photodynamic therapy (TAP) study group principal investigators, Verteporfin in photodynamic therapy (VIP) study group principal investigators. Guidelines for using verteporfin (visudyne) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes. Retina 2002;22:6-18.
46. Verteporfin Roundtable Participants. Guidelines for using verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: update. Retina 2005;25:119-34.
47. Deissler H, Deissler H, Lang S, et al. VEGF-induced effects on proliferation, migration and tight junctions are restored by ranibizumab (Lucentis) in microvascular retinal endothelial cells. Br J Ophthalmol 2008;92:839-43.
48. Kourlas H, Abrams P. Ranibizumab for the treatment of neovascular age-related macular degeneration: a review. Clin Ther 2007;29:1850-61.
49. Elman MJ, Fine SL, Murphy RP, et al. The natural history of serous retinal pigment epithelium detachment in patients with age-related macular degeneration. Ophthalmology 1986;93:224-30.
50. Dadgostar H, Ventura AA, Sharma S, et al. OCT lesion morphology and the response of exudative AMD to Ranibizumab. Abstract PO552. AAO/SOE Joint Annual Meeting, 8-11 November 2008, Atlanta. http://www.aao.org/aao/customcf/ onlineprogram2008/tnt-getevtlongaao02.cfm? subsystem=MTG&primary-id=AM08&secondary-id=PO552 (accessed 22 May 2009).
51. Carvounis PE, Kopel AC, Benz MS. Retinal pigment epithelium tears following ranibizumab for exudative age-related macular degeneration. Am J Ophthalmol 2007;143:504-5.
52. Bakri SJ, Kitzmann AS. Retinal pigment epithelial tear after intravitreal ranibizumab. Am J Ophthalmol 2007;143:505-7.
53. Chan CK, Lin SG. Retinal pigment epithelial tear after ranibizumab therapy for subfoveal fibrovascular pigment epithelial detachment. Eur J Ophthalmol 2007;17:674-6.
54. Chang LK, Sarraf D. Tears of the retinal pigment epithelium: an old problem in a new era. Retina 2007;27:523-34.
55. Schmidt-Erfurth U, Wolf S, Study Group. Same-day administration of verteporfin and ranibizumab 0.5 mg in patients with choroidal neovascularization due to age-related macular degeneration. Br J Ophthalmol 2008;92:1628-35.
56. Klein ML, Jorizzo PA, Watzke RC. Growth features of choroidal neovascular membranes in age-related macular degeneration. Ophthalmology 1989;96:1416-19.
57. Arias L, Armada F, Donate J, et al. Delay in treating age-related macular degeneration in Spain is associated with progressive vision loss. Eye 2009;23:326-33.
58. US Food and Drug Administration. Labeling Instructions for Ranibizumab, (BLA) 125156. 2006. http://www.fda.gov/cder/foi/label/2006/ 125156lbl.pdf (accessed 21 Nov 2008).
59. Regillo CD, Yue H, Shams N. Ranibizumab (Lucentis) in treatment of neovascular age-related macular degeneration (AMD): 2-year results of PIER study. Poster PO459. AAO 2007.
60. Kaiser PK, Blodi BA, Shapiro H, et al. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007;114:1868-75.
61. Kaiser PK, Chung CY, Tuomi L. Overview of Ranibizumab efficacy for wet AMD: ANCHOR, MARINA, PIER, and SAILOR studies. Abstract PO255 presented at the AAO/SOE Joint Annual Meeting, 8-11 November 2008, Atlanta. http://www.aao.org/aao/customcf/onlineprogram2008/tnt-getevtlongaao02.cfm? subsystem=MTG&primary-id=AM08&secondary-id=PO255.
62. Holz FG. SOE: flexibly dosed ranibizumab in patients with neovascular AMD: twelvemonth interim results of the SUSTAIN Trial. Abstract PA078 presented at the AAO/ SOE Joint Annual Meeting, 8-11 November 2008, Atlanta. http://www.aao.org/aao/customcf/onlineprogram2008/tnt-getevtlongaao02. cfm?subsystem=MTG&primary-id=AM08&secondary-id=PA078.
63. Brown DM, Wang P-W, Scott LC. HORIZON extension trial of Ranibizumab for wet AMD: subanalysis of year 1 results. Abstract PO248 presented at the AAO/SOE Joint Annual Meeting, 8-11 November 2008, Atlanta. http://www.aao.org/aao/customcf/onlineprogram2008/tnt-getevtlongaao02.cfm? subsystem=MTG&primary-id=AM08&secondary-id=PO248.
64. Boyer DS, Chung CY, Tuomi L. A Safety Overview of Ranibizumab in Patients With Wet AMD: ANCHOR, MARINA, PIER, and SAILOR Studies. Abstract PO247 presented at the AAO/SOE Joint Annual Meeting, 8-11 November 2008, Atlanta. http://www.aao.org/aao/customcf/onlineprogram2008/tnt-getevtlongaao02.cfm? subsystem=MTG&primary-id=AM08&secondary-id=PO247.
65. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
66. Alexander SL, Linde-Zwirble WT, Werther W, et al. Annual rates of arterial thromboembolic events in medicare neovascular age-related macular degeneration patients. Ophthalmology 2007;114:2174-8.
67. Wong TY, Klein R, Sun C, et al. Age-related macular degeneration and risk for stroke. Ann Intern Med 2006;145:98-106.
68. Tan JS, Wang JJ, Liew G, et al. Age-related macular degeneration and mortality from cardiovascular disease or stroke. Br J Ophthalmol 2008;92:509-12.
69. Joeres S, Tsong JW, Updike PG, et al. Reproducibility of quantitative optical coherence tomography subanalysis in neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 2007;48:4300-7.
70. Patel PJ, Chen FK, Ikeji F, et al. Repeatability of stratus optical coherence tomography measures in neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 2008;49:1084-8.
71. Fleckenstein M, Charbel IP, Helb HM, et al. High-resolution spectral domain-OCT imaging in geographic atrophy associated with age-related macular degeneration. Invest Ophthalmol Vis Sci 2008;49:4137-44.
72. de Bruin DM, Burnes DL, Loewenstein J, et al. In vivo three-dimensional imaging of neovascular age-related macular degeneration using optical frequency domain imaging at 1050 nm. Invest Ophthalmol Vis Sci 2008;49:4545-52.
73. Wolf-Schnurrbusch UE, Ceklic L, Brinkmann CK, et al. Macular thickness measurements in healthy eyes using six different optical coherence tomography instruments. Invest Ophthalmol Vis Sci. In press.
74. Ceklic L, Maar N, Neubauer AS. Optical coherence tomography fast versus regular macular thickness mapping in diabetic retinopathy. Ophthalmic Res 2008;40:235-40.
75. Davanger M, Ringvold A, Blika S, et al. Frequency distribution of IOP. Analysis of a material using the gamma distribution. Acta Ophthalmol (Copenh) 1991;69:561-4.